Heron Therapeutics announced that the FDA acknowledged the receipt of the Company’s Prior Approval Supplement, PAS, application for ZYNRELE extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024. If approved, the introduction of the VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF’s withdrawal time from up to three minutes down to between twenty and forty-five seconds. The user-friendly “container-like” design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. If approved, the VAN is expected to be available for use in the fourth quarter of this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics initiated with a Buy at Rodman & Renshaw
- Heron Therapeutics Submits ZYNRELEF® Supplement to FDA
- Heron announces PAS submission to FDA for ZYNRELEF
- Heron Therapeutics sees FY24 adjusted EBITDA ($22.0M)-$3.0M
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates